Literature DB >> 16092793

Insights in the pathogenic potential of Propionibacterium acnes from its complete genome.

Holger Brüggemann1.   

Abstract

One of the long-lasting open questions in understanding acne is the role of the skin bacterium Propionibacterium acnes. Opinions within the scientific community diverge regarding the importance of this Gram-positive bacterium not only in acne but also in other P. acnes-associated diseases. The recently decoded genome gives us some clues with respect to its pathogenic potential and its strategies to survive in the harsh environment of human skin. This review focuses on the major findings of the genome sequence. Special attention has been drawn to the cell surface composition of P. acnes, its antigenic potential, and to enzymes that are potentially involved in degrading skin-derived substances.

Entities:  

Mesh:

Year:  2005        PMID: 16092793     DOI: 10.1016/j.sder.2005.03.001

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  41 in total

1.  The distribution of infection with Propionibacterium acnes is equal in patients with cervical and lumbar disc herniation.

Authors:  Naghmeh Javanshir; Firooz Salehpour; Javad Aghazadeh; Farhad Mirzaei; Seyed Ahmad Naseri Alavi
Journal:  Eur Spine J       Date:  2017-07-15       Impact factor: 3.134

Review 2.  Genomics of Actinobacteria: tracing the evolutionary history of an ancient phylum.

Authors:  Marco Ventura; Carlos Canchaya; Andreas Tauch; Govind Chandra; Gerald F Fitzgerald; Keith F Chater; Douwe van Sinderen
Journal:  Microbiol Mol Biol Rev       Date:  2007-09       Impact factor: 11.056

Review 3.  Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Authors:  Yvonne Achermann; Ellie J C Goldstein; Tom Coenye; Mark E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Propionibacterium acnes Host Inflammatory Response During Periprosthetic Infection Is Joint Specific.

Authors:  Scott R Nodzo; K Keely Boyle; Samrath Bhimani; Thomas R Duquin; Andy O Miller; Geoffrey H Westrich
Journal:  HSS J       Date:  2016-09-29

5.  Modic changes in the adjacent vertebrae due to disc material infection with Propionibacterium acnes in patients with lumbar disc herniation.

Authors:  Javad Aghazadeh; Firooz Salehpour; Ehsan Ziaeii; Naghme Javanshir; Afshin Samadi; Javid Sadeghi; Farhad Mirzaei; Seyed Ahmad Naseri Alavi
Journal:  Eur Spine J       Date:  2016-11-24       Impact factor: 3.134

6.  Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris.

Authors:  Pei-Feng Liu; Teruaki Nakatsuji; Wenhong Zhu; Richard L Gallo; Chun-Ming Huang
Journal:  Vaccine       Date:  2011-02-26       Impact factor: 3.641

7.  A peptide with a ProGln C terminus in the human saliva peptidome exerts bactericidal activity against Propionibacterium acnes.

Authors:  Chun-Ming Huang; Justin W Torpey; Yu-Tseung Liu; Yun-Ru Chen; Katherine E Williams; Elizabeth A Komives; Richard L Gallo
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

8.  Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris.

Authors:  Teruaki Nakatsuji; Mandy C Kao; Jia-You Fang; Christos C Zouboulis; Liangfang Zhang; Richard L Gallo; Chun-Ming Huang
Journal:  J Invest Dermatol       Date:  2009-04-23       Impact factor: 8.551

9.  Prosthetic valve endocarditis caused by Propionibacterium species successfully treated with coadministered rifampin: report of two cases.

Authors:  Dominique Laurent Braun; Barbara Katharina Hasse; Julia Stricker; Jan Sven Fehr
Journal:  BMJ Case Rep       Date:  2013-01-25

10.  Propionibacterium acnes populations involved in deep pathological samples and their dynamics along the cardiac surgical pathway.

Authors:  S Romano-Bertrand; M Beretta; H Jean-Pierre; J-M Frapier; B Calvet; S Parer; E Jumas-Bilak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-30       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.